Insiders who reported open-market trades in the last 12 months at the companies Harold Bernstein files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jason V. Coloma - $6.19M in MAZE purchases and sales in the last 12 months
Atul Dandekar - $2.27M in MAZE purchases and sales in the last 12 months
Catherine A. Sohn - $1.15M in MAZE purchases and sales in the last 12 months
Amy Bachrodt - $757K in MAZE purchases and sales in the last 12 months
Phillips Courtney - $105K in MAZE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Harold Bernstein is a corporate insider, tracked as President, R&D & CMO of Maze Therapeutics, Inc. (MAZE). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Harold Bernstein submitted recently?
5 primary Form 4 filings in the last 90 days, covering 1 company.
Has Harold Bernstein been buying or selling stock?
Recorded transactions: 0 open-market purchases and 26 open-market sales ($7.44M) across all tracked filings.
Harold Bernstein is President, R&D & CMO of Maze Therapeutics, Inc. (MAZE). 15 SEC Form 4 filings on record going back to 2025, most recently on 2 October 2026. Most recent open-market trade: sold $435K of MAZE on 2 October 2026. Lifetime open-market sales: $7.44M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Harold Bernstein.
InsiderAlpha's records for Harold Bernstein go back to 2025: 15 primary Form 4 filings, an average of 7.5 per year. 46 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
